Atlas Trials

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Clinical trial NCT07416253 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07416253
Sponsor
Henan Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2026-03-01
Primary completion
2027-03-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.